Dr. Porubcin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 John Deere Rd
Ste 200
Moline, IL 61265Phone+1 309-779-4200Fax+1 309-779-4305
Summary
- Dr. Michael Porubcin is Board Certified Hematologist/Oncologist. He received his medical degree from Comenius University in 1986. After beeing in private practice for nearly 20 years, he has joined Genesis Cancer Care Institute in Davenport, IA.
Education & Training
USA HealthFellowship, Hematology and Medical Oncology, 1996 - 1999- USA HealthResidency, Internal Medicine, 1993 - 1996
Memorial Sloan Kettering Cancer CenterBasic Science Research, Cell Biology and Genetics Department, 1992 - 1993- Memorial Sloan Kettering Cancer CenterBasic Science Research, Molecular Pharmacology & Chemistry Dept., 1991 - 1992
Comenius UniversityClass of 1986
Certifications & Licensure
IL State Medical License 1999 - 2026
IA State Medical License 2011 - 2025
CO State Medical License 1998 - 2017
AL State Medical License 1994 - 2016- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- The Mammadi Soudavar Memorial Fellowship, Memorial Sloan-Kettering Cancer Center in New York, NY The New York Community Trust, 1992
Publications & Presentations
PubMed
- 98 citationsSeparate pathways for cellular uptake of ferric and ferrous ironMarcel E. Conrad, Jay N. Umbreit, Elizabeth G. Moore, Lucille N. Hainsworth, Michael Porubcin
American Journal of Physiology. Gastrointestinal and Liver Physiology. 2000-10-01 - 264 citationsDMT1: A mammalian transporter for multiple metalsMichael D. Garrick, Kevin G. Dolan, Craig Horbinski, Andrew J. Ghio, Dennis Higgins
Biometals. 2003-03-01
Journal Articles
- Factors predicting coronary artery disease in patients with giant negative T waves.Otrusinik R, Alpert MA, Hamm CR, Bikkina M, Porubcin M, Panayiotou H, Am J Cardiol., 85(7):873-5, A9, 4/1/2000
Abstracts/Posters
- Pretreatment of colon carcinoma cells to D1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity. Proc. Amer. Cancer Res. 35:330, 1994.Chang YM, Zielinski Z, Izzo J, Porubcin M, Bertino JR, Proc. Amer. Cancer Res. 35:330, San Francisco, CA, 4/11/1994
- Rapid Elimination of P-glycoprotein-encoding Genes After Exposure of Vincristine-resistant Chinese Hamster Lunc Gells, DC-3F/VCR-5L, to Verapamil. Gen. Motors Cancer R...Biedler JL, Chang TD, Druskin H, Meyers MB, Porubcin M, Spengler BA, Gen. Motors Cancer Res. Found. Int. Symp., Toronto, Canada, 5/7/1993
- Sensitivity of Two Fluorouracil Resistant HCT-8 cell Lines to Fluorouridine (FUR), Methotrexate (MTX) and D1694, a Folate Inhibitor of Thymidylate Synthase. 33:543, 1...Chang YM, Aschele CS, Porubcin M, Bertino JR, Proc. Amer. Cancer Res., San Diego, CA, 5/21/1992
Press Mentions
Genesis Unveils Enhancements to Cancer Care in the Quad CitiesMarch 14th, 2019
Committees
- Chair, Cancer Committee 2019 - 2020
Professional Memberships
- Member
- Member
- Member
- Intl. Assoc. for the Study of Lung Cancer (IASLC)Member
- Catholic Medical Association (CMA)Member
Other Languages
- Czech
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
